Program
CLR1404
Also written as “I-131-CLR1404”, “CLR 131” and “Iopofosine I 131”.
Its studies are mostly in Glioma · Waldenstrom Macroglobulinemia · Neoplasms · Neuroblastoma · Multiple Myeloma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Cellectar Biosciences | 74 open or running | phase 3since Jul 30, 2026 | Dec 16, 2011 | Jun 30, 2027phase 1 · NCT05610891 |
| Cellectar | 10 open or running | phase 1since Jun 18, 2009 | Jun 18, 2009 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 18, 2009First study: phase 1 study in RecurrenceNew to CellectarCellectar · NCT00925275 · 9 enrolled · United States
- Dec 16, 2011Cellectar Biosciences's first study: phase 1 study in NeoplasmsNew to Cellectar BiosciencesCellectar Biosciences · NCT01495663 · 12 enrolled · United States
- Jan 25, 2013Phase 2 study in GliomaCellectar Biosciences · NCT01778088 · United States
- Oct 22, 2014Phase 1 study in Multiple MyelomaCellectar Biosciences · NCT02278315 · 31 enrolled · United States
- Oct 28, 2016Phase 2 study in Waldenstrom MacroglobulinemiaCellectar Biosciences · NCT02952508 · 120 enrolled · United States, Australia, Brazil and more
- Mar 20, 2018Phase 1 study in NeuroblastomaCellectar Biosciences · NCT03478462 · 30 enrolled · United States, Australia, Canada
- Oct 28, 2022Phase 1 study in GliomaCellectar Biosciences · NCT05610891 · 50 enrolled · United States, Canada
- Jul 30, 2026Phase 3 study in Waldenstrom MacroglobulinemiaPhase 3 reachedCellectar Biosciences · NCT07766421 · 219 planned
Ahead
- Jun 30, 2027Primary completion: phase 1 study in GliomaCellectar Biosciences · NCT05610891
- Jun 30, 2027Primary completion: phase 1 study in NeuroblastomaCellectar Biosciences · NCT03478462
- Jan 2032Primary completion: phase 3 study in Waldenstrom MacroglobulinemiaCellectar Biosciences · NCT07766421
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07766421Waldenstrom Macroglobulinemia | 3 | Not yet recruiting | Cellectar Biosciences | Jan 2032 | 219 |
| NCT05610891Glioma · United States, Canada | 1 | Active, not recruiting | Cellectar Biosciences | Jun 30, 2027 | 50 |
| NCT03478462Neuroblastoma · United States, Australia, Canada | 1 | Active, not recruiting | Cellectar Biosciences | Jun 30, 2027 | 30 |
| NCT02952508Waldenstrom Macroglobulinemia · United States, Australia, Brazil and more | 2 | Active, not recruiting | Cellectar Biosciences | Jun 22, 2026 | 120 |
| NCT02278315Multiple Myeloma · United States | 1 | Completed | Cellectar Biosciences | Dec 9, 2020 | 31 |
| NCT01778088Glioma · United States | 2 | Withdrawn | Cellectar Biosciences | Jun 2014 | 0 |
| NCT01495663Neoplasms · United States | 1 | Completed | Cellectar Biosciences | Nov 2013 | 12 |
| NCT00925275Recurrence · United States | 1 | Completed | Cellectar | Feb 2010 | 9 |
How it is read
Names in the registry
- “I-131-CLR1404”, 4 entries
- “CLR 131”, 2 entries
- “Iopofosine I 131”, 1 entry
- “Iopofosine I 131 fractionated dose”, 1 entry
- “I-131-CLR1404 Injection”, 1 entry
Conditions, from the studies’ own filings
- Glioma, 2 studies
- Waldenstrom Macroglobulinemia, 2 studies
- Neoplasms, 2 studies
- Neuroblastoma, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.